PharmaShots | Incisive News in 3 Shots

Subscribe Now

Commercialization

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia A...

February 28, 2022

Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic Macular Edema and Wet-AMD

Curacle Signs a License and Collaboration Agreement with Théa for Development and Commercialization of CU06-RE to treat Diabetic M...

October 28, 2021

Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Diseases

Everest Enter into an Exclusive License Agreement with Sinovent and SinoMab to Develop and Commercialize XNW1011 for Renal Disease...

September 20, 2021

Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU

Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis...

September 17, 2021

Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706- a Proposed Biosimilar Avastin (bevacizumab)

Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706- a Proposed Biosimilar Avasti...

September 9, 2021

AM-Pharma Enters into an Exclusive License Agreement with Kyowa Kirin to Commercialize Ilofotase Alfa in Japan

AM-Pharma Enters into an Exclusive License Agreement with Kyowa Kirin to Commercialize Ilofotase Alfa in Japan

September 8, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us